Tissue Historical Cash Flow
| TRX Stock | 58.50 1.50 2.50% |
Analysis of Tissue Regenix cash flow over time is an excellent tool to project Tissue Regenix Group future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Total Cash From Operating Activities of 982.8 K or End Period Cash Flow of 4 M as it is a great indicator of Tissue Regenix ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Tissue Regenix Group latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tissue Regenix Group is a good buy for the upcoming year.
Tissue |
About Tissue Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Tissue balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Tissue's non-liquid assets can be easily converted into cash.
Tissue Regenix Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Tissue Regenix Group to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Tissue Regenix operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Most accounts from Tissue Regenix's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Tissue Regenix Group current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tissue Regenix Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, Tissue Regenix's Begin Period Cash Flow is projected to decrease significantly based on the last few years of reporting. The current year's Total Cash From Operating Activities is expected to grow to about 982.8 K, whereas Change In Working Capital is projected to grow to (204.3 K).
| 2022 | 2023 | 2024 | 2025 (projected) | Capital Expenditures | 884.9K | 863K | 992.5K | 569.6K | Depreciation | 921.4K | 786.0K | 903.9K | 502.5K |
Tissue Regenix cash flow statement Correlations
Click cells to compare fundamentals
Tissue Regenix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tissue Regenix cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 7.2M | (3.9M) | (746.1K) | (1.3M) | (1.2M) | (1.1M) | |
| Free Cash Flow | (6.8M) | (3.9M) | (2.3M) | 177K | 159.3K | 167.3K | |
| Change In Working Capital | (2.9M) | (340.3K) | (500.1K) | (239K) | (215.1K) | (204.3K) | |
| Begin Period Cash Flow | 2.4M | 9.6M | 5.7M | 5.9M | 5.4M | 9.8M | |
| Total Cashflows From Investing Activities | (634K) | (1.4M) | (2.0M) | (1.1M) | (973.8K) | (1.0M) | |
| Other Cashflows From Financing Activities | (1.5M) | (629.7K) | (291.5K) | (1.3M) | (1.2M) | (1.3M) | |
| Depreciation | 762K | 793.3K | 921.4K | 786.0K | 903.9K | 502.5K | |
| Capital Expenditures | 1.4M | 1.5M | 884.9K | 863K | 992.5K | 569.6K | |
| Total Cash From Operating Activities | (5.5M) | (2.4M) | (1.4M) | 1.0M | 936K | 982.8K | |
| Net Income | (9.7M) | (3.5M) | (2.2M) | (1.7M) | (1.5M) | (1.6M) | |
| Total Cash From Financing Activities | 14.0M | 144.7K | 1.1M | (1.5M) | (1.4M) | (1.3M) | |
| End Period Cash Flow | 9.6M | 5.7M | 4.9M | 4.7M | 4.2M | 4.0M | |
| Other Non Cash Items | 10.9M | 2.5M | 2.7M | 1.8M | 2.1M | 2.3M | |
| Change To Account Receivables | (11K) | (372.3K) | (569.9K) | 841.7K | 967.9K | 1.0M | |
| Stock Based Compensation | (37K) | 110K | 249K | 342K | 307.8K | 323.2K | |
| Change To Inventory | (2.9M) | (83.6K) | (944.2K) | 411.0K | 369.9K | 388.4K | |
| Other Cashflows From Investing Activities | (212.1K) | (365.3K) | (579.9K) | (513.0K) | (461.7K) | (438.6K) | |
| Change To Netincome | 1.6M | 6.7M | 1.1M | 797K | 916.6K | 992.5K | |
| Change To Liabilities | (1.6M) | (46K) | 159K | 1.2M | 1.1M | 1.2M | |
| Investments | (1.4M) | (2.0M) | (1.1M) | (837K) | (962.6K) | (1.0M) | |
| Issuance Of Capital Stock | 20.0M | 0.0 | 9K | 74K | 66.6K | 63.3K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Other Information on Investing in Tissue Stock
The Cash Flow Statement is a financial statement that shows how changes in Tissue balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Tissue's non-liquid assets can be easily converted into cash.